Sharemaestro Newsreel

Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research

Zacks Research has upgraded Vaxcyte (NASDAQ:PCVX) from a "strong sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $86. The company recently reported a quarterly loss of $1.97 per share, outperforming estimates. Insider …

Evogene chairman to address dissident shareholder issues in Aug 18 earnings call

Evogene Ltd. announced that its Chairman, Nir Nimrodi, will discuss issues with dissident shareholders during the company's quarterly earnings call on August 18, 2026. The computational chemistry company aims to provide clarity on the situation and its potential impact on the company and investors. …

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene (Nasdaq: EVGN) announced that Chairman Nir Nimrodi will participate in the company's upcoming quarterly results Zoom conference call on Tuesday, August 18, 2026, at 9:00 AM Eastern Time (4:00 PM Israel time). Nimrodi will address the current situation involving certain dissident shareholders and …

Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $204.40, especially following the …

Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating

Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal …

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

BofA has increased its price target for Candel Therapeutics (CADL) to $12, up from the previous $9. This adjustment follows several recent announcements from Candel Therapeutics, including its Q2 earnings results, the initiation of a global Phase 3 trial for a lung-cancer drug, and …

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, …

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

This article highlights three promising "penny stocks" with strong financial health: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite their status as penny stocks, the companies demonstrate potential for growth and value backed by solid fundamentals. The analysis details their financial …

Zentalis adds USD 80.5m as azenosertib nears pivotal test

Zentalis Pharmaceuticals has raised approximately USD 80.5 million through an equity offering to fund the late-stage development and pre-commercial activities for its oral WEE1 inhibitor, azenosertib. The drug is being evaluated for Cyclin E1-positive platinum-resistant ovarian cancer, with Phase II data expected by year-end …

CTXR Q3'26 Earnings: EPS estimate is (0.36) USD

Citius Pharmaceuticals, Inc. (CTXR) is scheduled to release its Q3'26 earnings on August 17, 2026, with the disclosure expected at 8:00 AM ET (12:00 PM UTC). The company anticipates a Q3'26 revenue of 5.46 million USD and an EPS of (0.36) USD. This article …

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics reported its third-quarter fiscal year 2026 financial results, highlighting the FDA approval of LYTENAVA™ for wet age-related macular degeneration (wet AMD). The company is preparing for a U.S. commercial launch by the end of 2026, with an estimated potential to exceed $500 …

FDA-approved LYTENAVA targets wet AMD; U.S. launch planned by year-end 2026

Outlook Therapeutics (OTLK) reported a Q3 fiscal 2026 net loss of $20.3 million but highlighted the FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration, the only FDA-approved ophthalmic bevacizumab for this condition. The company is preparing for a U.S. launch by year-end …

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate …

Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary

Lantern Pharma Inc. reported a consolidated net loss of $(7.07M) and an EPS of $(0.57) for Q2 2026, marking a significant increase in losses compared to the previous year, with no revenue reported. Despite the financial losses, the company continued to advance its clinical …

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …

KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds

BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …

BridgeBio Pharma (BBIO) holders to resell 5M shares in $390M offering

BridgeBio Pharma is facilitating a secondary offering where a KKR-affiliated selling stockholder will sell 5,000,000 shares of common stock at $78.00 per share, totaling $390 million. BridgeBio Pharma will not receive any proceeds from this transaction, as all net proceeds will go to the …

Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k

Insiders at Eikon Therapeutics, Inc. (NASDAQ:EIKN) are still down US$852k on their US$2.00m investment made over the past year, despite a recent 12% stock increase. Independent Director Kenneth Frazier made the largest purchase at US$18.00 per share, above the current price of US$10.33, indicating …

Rein Therapeutics Q2 EPS $(0.10) beats $(0.17) estimate

Tvardi: Q2 Earnings Snapshot

VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920

Quantum BioPharma Says Cash Could Fund Plans to Oct. 2027

Acumen's Q2 Loss Narrows; Topline Phase 2 Data For Alzheimer's Drug Sabirnetug In Late '26

(RTTNews) - Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses. The company is engaged in developing novel therapeutics targeting toxic soluble amyloid beta …

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research

Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with …

OmniAb (OABI) Q2 2026 Earnings Call Transcript

OmniAb (OABI) reported strong Q2 2026 financial results, with revenue reaching $13.4 million, primarily driven by milestone achievements from clinical program advancements. The company raised its full-year 2026 revenue guidance to $32 million to $36 million and expects to end the year with $37 …

Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

Kyntra Bio Inc Q2 Net Income From Cont Ops US

This article provides the Q2 net income from continuing operations for Kyntra Bio Inc. The content seems to be a financial document detailing this specific metric.

Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary

Rein Therapeutics (RNTX) reported its second-quarter 2026 financial results, showing no revenue and a net loss of $6.4 million, an improvement from the $6.8 million loss in the prior-year quarter. The company announced clinical progress with its lead candidate LTI-03 in a Phase 2 …

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rein Therapeutics announced its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its global Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF), having surpassed 25% enrollment and being on track for interim data in H2 …

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages

Rein Therapeutics Inc. (NASDAQ:RNTX) has received a consensus "Hold" rating from four brokerages, with an average 12-month price target of $6.00. Institutional investors hold a significant 90.89% stake in the company, with several firms recently increasing their positions. The company reported a narrower-than-expected quarterly …

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research

Zacks Research has upgraded REGENXBIO (NASDAQ:RGNX) from a "strong sell" to a "hold" rating. This upgrade comes as the biotechnology company exceeded revenue and EPS estimates in its latest quarterly report, though it remains unprofitable. Institutional investors hold a significant portion of the company's …

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock

Lynx1 Capital Management LP, a 10% owner of Korro Bio (NASDAQ:KRRO), purchased $78,809 worth of common stock in two transactions in early August 2026. These purchases were made at weighted average prices between $11.3998 and $13.1869 per share. The stock has seen significant year-to-date …

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics has initiated its potentially registrational Phase 2 RECLAIM-LN clinical trial for FT819, an off-the-shelf CAR T-cell therapy, to treat refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The first patient has been dosed in an outpatient setting, and the study aims …

Fate Therapeutics' First FT819 Patient Went Home Same Day

Fate Therapeutics has initiated its RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, in patients with lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, with the study aiming to enroll approximately 53 …

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Adlai Nortye Ltd. announced its unaudited financial results for the first half of 2026, reporting a significant decrease in net loss to US$5.3 million and a rise in revenue to US$13.1 million, primarily from a licensing agreement. The company highlighted operational progress in its …